Clinical benefit of very-low-dose perindopril-indapamide combination in hypertension.

UNITE de Pharmacologie Clinique, Service de Pharmacologie, Hĵpital Européen Georges Pompidou, Paris, France. stephane-laurent@egp.ap-hop-paris.fr

OBJECTIVE: To review the efficacy and safety of the very-low-dose combination of 2 mg perindopril and 0.625 mg indapamide in essential hypertension. STUDY SELECTION: The five main studies from the European registration file were performed in hypertensive outpatients and included two phase II double-blind randomised dose-ranging studies, and three phase III double-blind randomised studies (one study comparing placebo with each of the components, one long-term study over 15 months and one study comparing the combination and losartan). MAIN OUTCOME MEASURES: Decreases in systolic (SBP) and diastolic (DBP) blood pressures measured at trough with a mercury sphygmomanometer, an automatic device (Omron), and 24 h ambulatory blood pressure measurements (ABPM). RESULTS: The combination 2 mg perindopril and 0.625 mg indapamide was selected from the dose-finding studies. Twelve weeks after participants in the randomised studies were allocated to groups, the reductions in SBP, measured with an Omron device, were 12.3 +/- 15.0 mmHg with the combination, 8.0 +/- 16.5 mmHg with 2 mg perindopril (P = 0.001), 9.4 +/- 14.3 mmHg with 0.625 mg indapamide (P = 0.023), and 2.1 +/- 16.8 mmHg with placebo (P < 0.001) (mean +/- SD; all P values are for comparisons with the combination). The reductions in DBP were 6.8 +/- 9.2 mmHg, 5.0 +/- 9.5 mmHg (P = 0.02), 4.7 +/- 8.2 mmHg (P = 0.004), and 2.4 +/- 9.6 mmHg (P < 0.001) in the combination, 2 mg perindopril, 0.625 mg indapamide and placebo groups, respectively. During the long-term study, among 235 patients who achieved initial blood pressure normalisation with the fixed combination, 79.8% sustained their normalisation over 1 year, with no significant difference regarding safety criteria: the occurrence of adverse drug reactions per patient per year was 0.37 and 0.28 in the combination and placebo groups, respectively. A significantly (P < 0.05) larger blood pressure decreasing effect on nocturnal mean SBP (by ABPM) was demonstrated for the combination compared with that achieved with losartan, with no difference in safety. CONCLUSIONS: The proven efficacy on DBP and SBP, and the good safety profile, confirm that the new low-dose combination of 2 mg perindopril and 0.625 mg indapamide is a valuable option in the first-line treatment of hypertension.

PMID: 11848262 [PubMed - indexed for MEDLINE]